ARTBIO, a clinical-stage radiopharmaceutical company, has announced the close of a $132 million Series B funding round. The round was co-led by new investors Sofinnova Investments and B Capital, with additional backing from the Qatar Investment Authority, Alexandria Venture Investments, and continued support from existing investors like F-Prime, Omega Funds, and Third Rock Ventures.
This funding comes as ARTBIO makes major strides in alpha radioligand therapies (ARTs), a promising new approach in the fight against cancer.
What Will the Funding Support?
The new capital injection will accelerate several strategic priorities:
- Advance AB001, the lead therapy, through Phase II clinical trials targeting metastatic castration-resistant prostate cancer
- Move additional undisclosed programs toward IND (Investigational New Drug) readiness
- Scale up global manufacturing and supply chain using ARTBIO’s proprietary AlphaDirect™ technology
“This investment enables us to power forward with life-saving therapies and build a robust supply chain aligned with our innovation,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO.
Why ARTBIO Stands Out
ARTBIO is not just another biotech startup. It’s redefining how cancer is treated by using alpha radioligand therapies, which deliver targeted radioactive payloads to destroy cancer cells with high precision.
- ✅ Proprietary AlphaDirect™ system allows daily, flexible production of lead-212 (212Pb)
- âś… Distributed manufacturing model reduces supply risk and increases reliability
- âś… Focused on tumor-specific targets to maximize treatment efficacy and safety
This positions ARTBIO to overcome the traditional challenges of radioisotope production and delivery—a known bottleneck in radiopharmaceuticals.
Strong Investor Confidence
Investors are excited about ARTBIO’s differentiation model and rapid progress.
“Their lead candidate AB001 and integrated manufacturing strategy show immense potential,” said Robert Mittendorff, M.D., General Partner at B Capital.
“Their generator technology is a game-changer,” added Maha Katabi, Ph.D., General Partner at Sofinnova Investments.
With this fresh round, ARTBIO aims to push the boundaries of cancer care while building the infrastructure to support global clinical trials and eventual commercialization.
About ARTBIO
Founded on nearly a century of pioneering radiation research from the University of Oslo and Norway’s Radium Hospital, ARTBIO brings together science, innovation, and purpose. Its lead therapy, AB001, is already in first-in-human trials, with multiple programs in the pipeline.
Final Thought
As the world seeks better cancer treatments, ARTBIO’s precision radioligand approach backed by innovative supply technology could set a new benchmark in oncology. With major investor support and groundbreaking science, the company is looking for significant impact.